Elsevier Launches New Open Access Journal: Translational Proteomics

     Elsevier Launches New Open Access Journal: Translational Proteomics

  PR Newswire

  GENEVA, Switzerland, May 27, 2013

GENEVA, Switzerland, May 27, 2013 /PRNewswire/ --

First articles now available online on ScienceDirect

Elsevier , a world-leading provider of scientific, technical and medical
information products and services, is pleased to announce the launch of
Translational Proteomics , an online-only, open access journal devoted to
transferring fundamental discoveries in the field of proteomics to clinical
applications, accelerating understanding and treatment of human diseases.

Jean-Charles Sanchez, Associate Professor at the University of Geneva, Head of
the Biomedical Research Proteomics Group and Director of the Proteomics Core
Facility of the Faculty of Medicine, will serve as Editor-in-Chief. The
journal aims to cover all areas of research in human proteomics using
multi-disciplinary approaches to untangle complex disease processes, such as
oncology, neurology, immunology, cardiovascular diseases, infectious diseases
and any internal medical disorder. Special sections within the journal will
highlight research in areas like systems biology and integrative
bioinformatics, clinical proteomics and personalized medicine, comparative
proteomics and drug development, medical bioinformatics and biostatistics,
food and health.

"With the launch of Translational Proteomics , we want to help the scientific
and medical communities overcome the challenges they face on the long path
from basic research to patient care," said Professor Sanchez. "By focusing on
connecting basic proteomics research to ultimate clinical applications, the
journal will provide a space for publications detailing proteomics
experiments, from early discovery to validation and the bedside."

"We are excited about the launch of Translational Proteomics ", added Dolors
Alsina, Executive Publisher at Elsevier. "This journal provides a unique
platform for the publication of high-quality, multi-disciplinary studies,
combining research which, until now, would have been broken into two or more
specialized publications."

For more information or to submit an article, visit
http://www.elsevier.com/locate/trprot

Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today,
researchers can choose to publish in over 1,500 hybrid journals as well as 39
full open access journals and these numbers will continue to grow rapidly. All
of Elsevier's open access publications have been peer reviewed, ensuring that
the broader community not only reads the latest research but that it is
factual, original and of the highest quality and ethical standards. For more
information about Elsevier's open access program, visit
http://www.elsevier.com/openaccess

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

Media contact Kristian Wilson Elsevier +44(0)1865-843817 k.wilson@elsevier.com
 
Press spacebar to pause and continue. Press esc to stop.